Skip to main content
PMC home page
Archives of Disease in Childhood logoLink to Archives of Disease in Childhood
. 2001 Sep;85(3):236–239. doi: 10.1136/adc.85.3.236

Congenital disorder of glycosylation type Ia (CDG-Ia): phenotypic spectrum of the R141H/F119L genotype

S Kjaergaard 1, M Schwartz 1, F Skovby 1
PMCID: PMC1718926  PMID: 11517108

Abstract

AIMS—To delineate common and variable features and outcome of children with congenital disorder of glycosylation type Ia (CDG-Ia) caused by the frequent R141H/F119L PMM2 genotype.
METHODS—Clinical data on 25 patients (mean age 7.6 years, range 0-19) were analysed.
RESULTS—All patients had an early presentation with severe feeding problems and failure to thrive, hypotonia, hepatic dysfunction, inverted nipples, and abnormal subcutaneous fat pads. Eighteen patients were hospitalised in the neonatal period. Developmental delay was obvious before age 6 months. During the first seven months mean standard deviation score (SDS) for weight and length decreased 2.7 (SD = 2) and 2.4 (SD = 2), respectively. Mental retardation, ataxia, muscular atrophy, and febrile seizures were consistent features after infancy. Variable features included pericardial effusions, afebrile seizures, and stroke like episodes. Computed tomography/magnetic resonance imaging of the brain was normal in two patients examined before 4 months of age, but 18children examined after 3 months of age had cerebellar atrophy, and 10 children also had supratentorial atrophy. Subsequent imaging showed progression of the cerebellar and supratentorial atrophy in eight and four of 10 children, respectively. Mean head circumference SDS declined from zero to −1.9 SD from age 3 months to 5 years. Motor ability ranged from none to walking with a rolator, and vocabulary ranged from none to comprehensible speech. The overall mortality ascribed to CDG-Ia was 18%.
CONCLUSION—Patients with the R141H/F119L genotype have an early uniform presentation including severe failure to thrive, but their functional outcome is variable. This genotype may well cause clinical manifestations in the severe end of the spectrum of CDG-Ia.



Full Text

The Full Text of this article is available as a PDF (104.4 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Andersen E., Hutchings B., Jansen J., Nyholm M. Højde og vaegt hos danske børn. Ugeskr Laeger. 1982 Jun 14;144(24):1760–1765. [PubMed] [Google Scholar]
  2. Barone R., Pavone L., Fiumara A., Bianchini R., Jaeken J. Developmental patterns and neuropsychological assessment in patients with carbohydrate-deficient glycoconjugate syndrome type IA (phosphomannomutase deficiency). Brain Dev. 1999 Jun;21(4):260–263. doi: 10.1016/s0387-7604(99)00020-0. [DOI] [PubMed] [Google Scholar]
  3. Bjursell C., Wahlström J., Berg K., Stibler H., Kristiansson B., Matthijs G., Martinsson T. Detailed mapping of the phosphomannomutase 2 (PMM2) gene and mutation detection enable improved analysis for Scandinavian CDG type I families. Eur J Hum Genet. 1998 Nov-Dec;6(6):603–611. doi: 10.1038/sj.ejhg.5200234. [DOI] [PubMed] [Google Scholar]
  4. Horslen S. P., Clayton P. T., Harding B. N., Hall N. A., Keir G., Winchester B. Olivopontocerebellar atrophy of neonatal onset and disialotransferrin developmental deficiency syndrome. Arch Dis Child. 1991 Sep;66(9):1027–1032. doi: 10.1136/adc.66.9.1027. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Imtiaz F., Worthington V., Champion M., Beesley C., Charlwood J., Clayton P., Keir G., Mian N., Winchester B. Genotypes and phenotypes of patients in the UK with carbohydrate-deficient glycoprotein syndrome type 1. J Inherit Metab Dis. 2000 Mar;23(2):162–174. doi: 10.1023/a:1005669900330. [DOI] [PubMed] [Google Scholar]
  6. Jaeken J., Stibler H., Hagberg B. The carbohydrate-deficient glycoprotein syndrome. A new inherited multisystemic disease with severe nervous system involvement. Acta Paediatr Scand Suppl. 1991;375:1–71. [PubMed] [Google Scholar]
  7. Jansen J. Måling af hovedomfang ved helbredsundersøgelser af børn. En multicenterundersøgelse. Ugeskr Laeger. 1982 Nov 8;144(45):3337–3342. [PubMed] [Google Scholar]
  8. Kjaergaard S., Skovby F., Schwartz M. Absence of homozygosity for predominant mutations in PMM2 in Danish patients with carbohydrate-deficient glycoprotein syndrome type 1. Eur J Hum Genet. 1998 Jul-Aug;6(4):331–336. doi: 10.1038/sj.ejhg.5200194. [DOI] [PubMed] [Google Scholar]
  9. Kjaergaard S., Skovby F., Schwartz M. Carbohydrate-deficient glycoprotein syndrome type 1A: expression and characterisation of wild type and mutant PMM2 in E. coli. Eur J Hum Genet. 1999 Dec;7(8):884–888. doi: 10.1038/sj.ejhg.5200398. [DOI] [PubMed] [Google Scholar]
  10. Kristiansson B., Stibler H., Wide L. Gonadal function and glycoprotein hormones in the carbohydrate-deficient glycoprotein (CDG) syndrome. Acta Paediatr. 1995 Jun;84(6):655–659. doi: 10.1111/j.1651-2227.1995.tb13720.x. [DOI] [PubMed] [Google Scholar]
  11. Matthijs G., Schollen E., Bjursell C., Erlandson A., Freeze H., Imtiaz F., Kjaergaard S., Martinsson T., Schwartz M., Seta N. Mutations in PMM2 that cause congenital disorders of glycosylation, type Ia (CDG-Ia). Hum Mutat. 2000 Nov;16(5):386–394. doi: 10.1002/1098-1004(200011)16:5<386::AID-HUMU2>3.0.CO;2-Y. [DOI] [PubMed] [Google Scholar]
  12. Matthijs G., Schollen E., Pardon E., Veiga-Da-Cunha M., Jaeken J., Cassiman J. J., Van Schaftingen E. Mutations in PMM2, a phosphomannomutase gene on chromosome 16p13, in carbohydrate-deficient glycoprotein type I syndrome (Jaeken syndrome). Nat Genet. 1997 May;16(1):88–92. doi: 10.1038/ng0597-88. [DOI] [PubMed] [Google Scholar]
  13. Petersen M. B., Brostrøm K., Stibler H., Skovby F. Early manifestations of the carbohydrate-deficient glycoprotein syndrome. J Pediatr. 1993 Jan;122(1):66–70. doi: 10.1016/s0022-3476(05)83488-2. [DOI] [PubMed] [Google Scholar]
  14. Pirard M., Matthijs G., Heykants L., Schollen E., Grünewald S., Jaeken J., van Schaftingen E. Effect of mutations found in carbohydrate-deficient glycoprotein syndrome type IA on the activity of phosphomannomutase 2. FEBS Lett. 1999 Jun 11;452(3):319–322. doi: 10.1016/s0014-5793(99)00673-0. [DOI] [PubMed] [Google Scholar]
  15. Schollen E., Kjaergaard S., Legius E., Schwartz M., Matthijs G. Lack of Hardy-Weinberg equilibrium for the most prevalent PMM2 mutation in CDG-Ia (congenital disorders of glycosylation type Ia). Eur J Hum Genet. 2000 May;8(5):367–371. doi: 10.1038/sj.ejhg.5200470. [DOI] [PubMed] [Google Scholar]
  16. Stibler H., Blennow G., Kristiansson B., Lindehammer H., Hagberg B. Carbohydrate-deficient glycoprotein syndrome: clinical expression in adults with a new metabolic disease. J Neurol Neurosurg Psychiatry. 1994 May;57(5):552–556. doi: 10.1136/jnnp.57.5.552. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Van Schaftingen E., Jaeken J. Phosphomannomutase deficiency is a cause of carbohydrate-deficient glycoprotein syndrome type I. FEBS Lett. 1995 Dec 27;377(3):318–320. doi: 10.1016/0014-5793(95)01357-1. [DOI] [PubMed] [Google Scholar]
  18. de Lonlay P., Seta N., Barrot S., Chabrol B., Drouin V., Gabriel B. M., Journel H., Kretz M., Laurent J., Le Merrer M. A broad spectrum of clinical presentations in congenital disorders of glycosylation I: a series of 26 cases. J Med Genet. 2001 Jan;38(1):14–19. doi: 10.1136/jmg.38.1.14. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. de Zegher F., Jaeken J. Endocrinology of the carbohydrate-deficient glycoprotein syndrome type 1 from birth through adolescence. Pediatr Res. 1995 Apr;37(4 Pt 1):395–401. doi: 10.1203/00006450-199504000-00003. [DOI] [PubMed] [Google Scholar]
  20. van Ommen C. H., Peters M., Barth P. G., Vreken P., Wanders R. J., Jaeken J. Carbohydrate-deficient glycoprotein syndrome type 1a: a variant phenotype with borderline cognitive dysfunction, cerebellar hypoplasia, and coagulation disturbances. J Pediatr. 2000 Mar;136(3):400–403. doi: 10.1067/mpd.2000.103503. [DOI] [PubMed] [Google Scholar]

Articles from Archives of Disease in Childhood are provided here courtesy of BMJ Publishing Group

RESOURCES